VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson

CARY, N.C., March 14, 2022 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by CTI BioPharma Corp. as a specialty pharmacy provider for VONJOTM (pacritinib) for the treatment of intermediate or high-risk primary or secondary (pos...
Source: McKesson News - Category: Information Technology Source Type: news